News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering
Caesarea, Israel, December 9th, 2021 ā IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the āCompanyā or āIceCureā), developer of minimally-invasive cryoablation technology, the ProSenseĀ®Ā System, that
IceCure Medicalās Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America
CAESAREA, Israel, December 2, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSenseĀ® System,
IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources
New executive appointment made commensurate with IceCureās growth related to the increased adoption of its flagship ProSenseĀ® Cryoablation System and development of next-generation of cryoablation
IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments
CAESAREA, Israel, November 23, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of next-generation, minimally-invasive cryoablation technology with ProSenseĀ®
IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSenseā¢
CAESAREA, Israel, November 1, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, āVAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,ā was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.
IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSenseā¢ Cryoablation System
CAESAREA, Israel, October 20, 2021 — IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering
Caesarea, Israel, December 9th, 2021 ā IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the āCompanyā or āIceCureā), developer of minimally-invasive cryoablation technology, the ProSenseĀ®Ā System, that
IceCure Medicalās Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America
CAESAREA, Israel, December 2, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSenseĀ® System,
IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources
New executive appointment made commensurate with IceCureās growth related to the increased adoption of its flagship ProSenseĀ® Cryoablation System and development of next-generation of cryoablation
IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments
CAESAREA, Israel, November 23, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of next-generation, minimally-invasive cryoablation technology with ProSenseĀ®
IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSenseā¢
CAESAREA, Israel, November 1, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, āVAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,ā was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.
IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSenseā¢ Cryoablation System
CAESAREA, Israel, October 20, 2021 — IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation